These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 17220672)
1. [Preoperative therapy with trastuzumab and paclitaxel in a stage IV advanced breast cancer with complete pathologic response]. Rai Y; Sagara Y; Sagara Y; Takahama T; Matsuyama Y; Ando M; Sagara Y; Ooi Y; Inoue K; Kurosumi M Gan To Kagaku Ryoho; 2007 Jan; 34(1):65-8. PubMed ID: 17220672 [TBL] [Abstract][Full Text] [Related]
2. [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment]. Ohsako T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O Gan To Kagaku Ryoho; 2006 Sep; 33(9):1301-3. PubMed ID: 16969029 [TBL] [Abstract][Full Text] [Related]
3. [Preoperative therapy using trastuzumab and weekly paclitaxel in a stage IIIB inoperable locally advanced HER2- positive breast cancer with complete pathologic response]. Rai Y; Sagara Y; Ooi Y; Sagara Y; Sagara Y; Baba S; Tamada S; Matsuyama Y; Ando M Gan To Kagaku Ryoho; 2009 Mar; 36(3):471-3. PubMed ID: 19295274 [TBL] [Abstract][Full Text] [Related]
4. [Markedly effective regimen using bi-weekly trastuzumab and paclitaxel in an advanced breast cancer with multiple liver metastases]. Rai Y; Takahama T; Sagara Y; Sagara Y; Matsuyama Y; Ando M; Sagara Y; Ooi Y Gan To Kagaku Ryoho; 2006 Sep; 33(9):1297-300. PubMed ID: 16969028 [TBL] [Abstract][Full Text] [Related]
5. Successful neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for an elderly patient with inflammatory breast cancer. Shimizu T; Hirano A; Watanabe O; Kinoshita J; Kimura K; Kamimura M; Domoto K; Kim N; Ogawa K; Fujibayashi M Anticancer Res; 2010 Feb; 30(2):581-5. PubMed ID: 20332474 [TBL] [Abstract][Full Text] [Related]
6. [Metastatic breast cancer treated with trastuzumab and paclitaxel--a case report with clinically complete response]. Yoshida T; Horiguchi J; Koibuchi Y; Kanoh T; Iijima K; Yoshida M; Kikuchi M; Takata D; Oyama T; Iino Y; Morishita Y Gan To Kagaku Ryoho; 2004 Jun; 31(6):907-10. PubMed ID: 15222110 [TBL] [Abstract][Full Text] [Related]
7. A case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a clinically complete response to concurrent trastuzumab and paclitaxel treatment. Shigematsu H; Nakamura Y; Tanaka K; Shiotani S; Koga C; Kawaguchi H; Nishimura S; Taguchi K; Nishiyama K; Ohno S Int J Clin Oncol; 2010 Dec; 15(6):615-20. PubMed ID: 20473628 [TBL] [Abstract][Full Text] [Related]
8. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab. Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840 [TBL] [Abstract][Full Text] [Related]
9. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566 [TBL] [Abstract][Full Text] [Related]
10. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy]. Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696 [TBL] [Abstract][Full Text] [Related]
11. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. Sikov WM; Dizon DS; Strenger R; Legare RD; Theall KP; Graves TA; Gass JS; Kennedy TA; Fenton MA J Clin Oncol; 2009 Oct; 27(28):4693-700. PubMed ID: 19720916 [TBL] [Abstract][Full Text] [Related]
12. [A case of advanced accessory breast cancer effectively treated with trastuzumab and paclitaxel]. Suzuki S; Ohchi T; Doi K; Ogata K; Maeda T; Kudo K; Ishihara A Gan To Kagaku Ryoho; 2008 Sep; 35(9):1615-7. PubMed ID: 18799924 [TBL] [Abstract][Full Text] [Related]
13. Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience. Horiguchi J; Oyama T; Takata D; Rokutanda N; Nagaoka R; Odawara H; Tokiniwa H; Tozuka K; Kikuchi M; Sato A; Takeyoshi I Anticancer Res; 2011 Sep; 31(9):3041-6. PubMed ID: 21868556 [TBL] [Abstract][Full Text] [Related]
14. [A case of locally advanced breast cancer successfully treated by pre-operative systemic therapy using paclitaxel and trastuzumab]. Suda T; Ishiguro K; Nishimura M Gan To Kagaku Ryoho; 2008 Jun; 35(6):979-81. PubMed ID: 18633228 [TBL] [Abstract][Full Text] [Related]
15. Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Gasparini G; Gion M; Mariani L; Papaldo P; Crivellari D; Filippelli G; Morabito A; Silingardi V; Torino F; Spada A; Zancan M; De Sio L; Caputo A; Cognetti F; Lambiase A; Amadori D Breast Cancer Res Treat; 2007 Mar; 101(3):355-65. PubMed ID: 16850247 [TBL] [Abstract][Full Text] [Related]
16. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer. Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263 [TBL] [Abstract][Full Text] [Related]
17. A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment. Hayashi H; Kimura M; Yoshimoto N; Tsuzuki M; Tsunoda N; Fujita T; Yamashita T; Iwata H Breast Cancer; 2009; 16(2):136-40. PubMed ID: 18548321 [TBL] [Abstract][Full Text] [Related]
18. [Complete response of advanced breast cancer with lymph node metastases to nab-paclitaxel therapy-report of a case]. Hara Y; Sakurai K; Enomoto K; Matsumoto K; Ueda Y; Hagiwara M; Waga E; Nagashima S; Tani M; Amano S Gan To Kagaku Ryoho; 2012 Nov; 39(12):2080-2. PubMed ID: 23267983 [TBL] [Abstract][Full Text] [Related]
19. [A case of HER2 overexpressing advanced breast cancer with CTF therapy [cyclophosphamide, pirarubicin (THPADM), fluorouracil] showed long-term effectiveness after paclitaxel shock]. Ikeda M; Sonoo H; Oota Y; Fujii S; Shimo T; Miyake A; Seki M; Nomura T; Yamamoto Y; Shiiki S; Nakashima K; Tanaka K; Kurebayashi J Gan To Kagaku Ryoho; 2010 Dec; 37(13):2917-20. PubMed ID: 21160270 [TBL] [Abstract][Full Text] [Related]
20. [Case report of advanced breast cancer responding to capecitabine and trastuzumab combination therapy]. Yoshidome K; Imabun S; Nakahara M; Hiraoka K; Yamagami Y; Tsujimoto M; Nakao K Gan To Kagaku Ryoho; 2006 Oct; 33(10):1453-6. PubMed ID: 17033236 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]